Fig. 4

RN7SL1 expression is upregulated in AD and positively correlates with “ABC” scores. (a, b) Using the GSE118553 dataset to validate RN7SL1 expression, which progressively increases across control, AsymAD, and AD groups in all tissues (a) and the EC (b). (c) RN7SL1 expression levels in the EC of brain tissues from individuals without AD pathology (control) and those with AD pathology were quantified using quantitative real-time reverse transcription PCR (qRT‒PCR) and normalized to GAPDH expression. Each group consisted of 6 donors, with 3 replicates per donor. (d) Expression of Rn7sl1 10 h after 10 µM oligomeric amyloid-β (oAβ) stimulation in rat primary neurons as determined by qRT‒PCR and normalized to ACTB expression (n = 3/group). (e) Expression of Rn7sl1 4 h after 10 nM okadaic acid (OA) stimulation in rat primary neurons as determined by qRT‒PCR and normalized to ACTB expression (n = 3/group). (f) Spearman correlation analysis of RN7SL1 expression and “ABC” scores across five subfields. A Aβ plaque score; B Braak Neurofibrillary Tangle stage; C CERAD neuritic plaque score. Values represent mean ± standard error of mean (SEM). *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, as determined by one-way analysis of variance (ANOVA; for comparing multiple groups) or Student’s t-test (for comparing two groups)